Skip to content

Effect of Citalopram on Three Months Functional Prognosis of Acute Ischemic Stroke Patients

Evaluation of the Effect of Citalopram on Three Months Functional Prognosis of Acute Ischemic Stroke Patients: A Randomized Clinical Trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201203192150N2
Enrollment
144
Registered
2012-04-22
Start date
2012-05-10
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemic stroke. Cerebral infarction

Interventions

Intervention 1: Citalopram tablets(produced with commercial name? as Citalopram product by Sobhan Pharma Co.)/ 20 mg Daily. Intervention 2: Placebo as the same shape and size and color as Citalopram t
Treatment - Drugs
Placebo
Citalopram tablets(produced with commercial name? as Citalopram product by Sobhan Pharma Co.)/ 20 mg Daily
Placebo as the same shape and size and color as Citalopram tablets

Sponsors

Neurosciences Research Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1- Acute ischemic stroke hospitalization in Razi university hospital; 2- No previous use of citalopram and other antidepressants, MAOI, Neuroleptic drugs and benzodiazepines in the last month before the onset of symptoms; 3- Not having a severe disability after stroke(NIHSS18). Exclusion criteria: 1- Request of patients to Exit from the study; 2- Previous chronic disease interferes with the performance evaluation in patients such as: chronic infections, liver or kidney failure, cancers; 3- Residual weakness of previous stroke; 4- Pregnancy or breastfeeding or any conditions that makes follow up impossible; 5- Sever loss of Consciousness; 6- Thrombolytic therapy; 7-Endarterectomy; 8- Depression(MADRS>18).

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Prognosis after stroke. Timepoint: At hospitalization(0), discharge(1), and after 3 months(2). Method of measurement: Modifi ed Rankin scale (MRS).

Primary

MeasureTime frame
Functional status after stroke. Timepoint: At hospitalization(0), discharge(1), and after 3 months(2). Method of measurement: Functional status score based on NIHSS(National institutes of health stroke scale)(at least 50% reduction in NIHSS score in 3-month compared to the baseline score.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ehsan Sharifipour

Tabriz University of Medical Sciences

sharifipour.e@gmail.com+98 41 1442 8346

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 10, 2026